TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8760238
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (Vamin 9; Kabi Pharmacia) at 4 ml/min for 210 min
Study: 22205149
Drug: Polymorphisms of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms of estrogen receptor α
Study: 16773438
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy
Study: 25467190
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 600 mg + morphine 60 mg
Study: 2401751
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg bid
Study: 31574047
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen cream
Study: 17924869
Drug: Fenofibrate 80
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 80 mg + Metformin 850 mg
Study: 2956958
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg MPA daily for metastatic breast cancer (Group IV)
Study: 8558934
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10 micrograms/kg/day continuous i.v. infusion started 24 hours after chemotherapy completion.
Study: 18027383
Drug: Methylprednisolone 10
Normalized name: methylprednisolone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 10 mg/kg
Study: 14762633
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg on first day and 450 mg on second and third days (Group CHLO)
Study: 14762633
Drug: Chloroquine single
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine single dose treatment
Study: 22613271
Drug: Intramuscular cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cholecalciferol (600,000 IU)
Study: 15346658
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/day
Study: 22509426
Drug: Donor bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor bone marrow infusion (DBMI)
Study: 12798615
Drug: TYPHIM Vi
Normalized name: Typhim VI
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TYPHIM Vi (control vaccine)
Study: 12798615
Drug: tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetanus toxoid vaccine (control)
Study: 8606270
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dobutamine (20 to 40 microg/kg body weight per min)
Study: 19935115
Drug: Bandage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bandage therapy (BT)
Study: 19935115
Drug: Bandage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bandage therapy (BT) and Cast therapy (CT)
Study: 28548024
Drug: Glimepiride up
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride up to 6 mg once daily
Study: 8901793
Drug: Calcium tablets
Normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium tablets
Study: 18369721
Drug: Three types
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three types of sex (vaginal, oral, and anal)
Study: 15166554
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and remifentanil combination
Study: 2651367
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (17 infants with birthweight ≤ 1500 g and 20 infants with birthweight 1501-2000 g)
Study: 31812149
Drug: Oral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nimodipine
Study: 10525141
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of beta-carotene
Study: 7723385
Drug: Low-dose monthly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monthly maintenance therapy
Study: 11824878
Drug: 5-HT3 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT3 antagonists (specific drugs not mentioned)
Study: 9327336
Drug: Rectal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal immunization
Study: 23016508
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (90 mg gel once daily)
Study: 16113133
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 12 weeks
Study: 12466367
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 6.25 micro g/kg sc daily
Study: 12466367
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) transdermal patch 5.0 mg/daily
Study: 12466367
Drug: Combined Hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Hormones (GHT)
Study: 3051673
Drug: Dexamethasone acetate
Normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone acetate (4 mg four times a day)
Study: 12844393
Drug: Enterostatin (ENT)
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enterostatin (ENT) 3 x 15 mg/d
Study: 31949084
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion (6 pmol/kg/min)
Study: 18775846
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (ET; 1 mg/day for 6 months)
Study: 394624
Drug: Pentazocine 15
Normalized name: pentazocine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 15 mg
Study: 1339011
Drug: Cisplatinum 20
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatinum 20 mg/m2/day + Etoposide 60 mg/m2/day (arm A)
Study: 21314751
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who consistently named multiple drug users in their social networks
Study: 12923684
Drug: Ibuprofen phonophoresis
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen phonophoresis (PH)
Study: 28225186
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oltipraz twice daily for 24 weeks
Study: 28225186
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of oltipraz twice daily for 24 weeks
Study: 24707145
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen of amoxicillin 1 g, clarithromycin 500 mg, and rabeprazole 20 mg twice daily
Study: 8723850
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (7.5 mg)
Study: 26753640
Drug: Delayed extended-release
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed extended-release formulation containing alpha-benzopyrone (Coumarin), benzo-gamma-pyrone (Troxuretina), and oligomeric proanthocyanidins from Vitis vinifera (OPC) in addition to compression therapy
Study: 20061421
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + Ox 0.06 mg/kg . d
Study: 8643970
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of paclitaxel at 135 mg/m2
Study: 2239934
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) therapy
Study: 27867128
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 6 hours
Study: 29037063
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (5000 or 50,000 IUs weekly) for depression treatment
Study: 19378437
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone treatment
Study: 8868311
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (0.3 microgram/kg/min)
Study: 22496156
Drug: Randomized dose
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized dose strategy, platelet source, ABO compatibility, and duration of storage
Study: 20472113
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (OC)
Study: 22094904
Drug: BMMSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMSC treatment
Study: 22094904
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression (CD) treatment
Study: 22237175
Drug: Cytomegalovirus therapeutic
Normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomegalovirus therapeutic DNA vaccine (TransVax)
Study: 30573004
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of prednisolone
Study: 23651816
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow mesenchymal stem cells (BMSCs); n=21
Study: 29226570
Drug: Sirolimus-based therapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-based therapy
Study: 9031103
Drug: Aggressive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive chemotherapy
Study: 18620577
Drug: AM-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-L
Study: 8911112
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 200 mg
Study: 1911501
Drug: 5-mg MS
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mg MS bolus and subsequent saline infusion (n = 13)
Study: 2691478
Drug: Cefotaxime 100
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 100 mg/kg/d in four divided iv doses for 14 days
Study: 7020917
Drug: L-phenylalanine mustard
Normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine mustard (L-PAM)
Study: 23327021
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.2 mg/kg)
Study: 29998336
Drug: Immediate monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate monitoring with a home-based wearable ECG patch
Study: 29998336
Drug: Delayed monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed monitoring with a home-based wearable ECG patch
Study: 10326116
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily of nitazoxanide
Study: 10326116
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg twice daily of nitazoxanide
Study: 27684308
Drug: Linagliptin/metformin
Normalized name: LINAGLIPTIN/METFORMIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin/metformin
Study: 29901374
Drug: Vaginal conjugated
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal conjugated equine estrogen (CEE) cream 0.5 g once a week
Study: 20041428
Drug: Topical (0.5%)
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical (0.5%) Pycnogenol and oral Pycnogenol
Study: 3349550
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml coffee with oral ranitidine 150 mg (Group 4)
Study: 8163257
Drug: Topical felbinac
Normalized name: felbinac Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical felbinac
Study: 1422972
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate 1500 mg/day
Study: 9830318
Drug: LARR1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LARR1 group (induction with 4 days of etoposide and 4 days of high-dose ara-C)
Study: 31030568
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day (control group)
Study: 28406125
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg OD for 24 weeks
Study: 8140383
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 micrograms) aqueous nasal spray (FPANS) twice daily
Study: 8140383
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms) aqueous nasal spray (BDPANS) twice daily
Study: 1662877
Drug: Temafloxacin 300
Normalized name: temafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 300 mg or 600 mg b.i.d.
Study: 24866253
Drug: Brief Narrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Narrative Exposure Therapy (brief NET), 3 sessions, conducted individually, in Arabic
Study: 11807679
Drug: Voriconazole 6
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 6 mg/kg b.i.d. for 2 doses, then 3 mg/kg b.i.d. for 6-27 days, followed by 200 mg b.i.d. orally for up to 24 weeks
Study: 22283900
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) initiation
Study: 10597783
Drug: APV 1200
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APV 1200 mg with 3TC/ZDV
Study: 31177055
Drug: Human donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human donor milk with >60 kcal/100 mL
Study: 7639806
Drug: CD4 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 monoclonal antibody (MAb) cM‐T412
Study: 8277144
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day
Study: 9579293
Drug: levodopa +
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa + apomorphine (1 mg/h)
Study: 23262475
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 1.5 g of magnesium sulphate followed by an infusion of 12 g in 24 h
Study: 7369096
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anticoagulants)
Study: 30668840
Drug: L-glutamic acid
Normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-glutamic acid inclusion levels: 3.28%
Study: 30668840
Drug: L-glutamic acid
Normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-glutamic acid inclusion levels: 3.48%
Study: 8031162
Drug: 5-FU tablets
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU tablets administered at a dose of 200 mg/day for 12 months
Study: 1531044
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg oral dose
Study: 30304457
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 30 mg daily
Study: 20022990
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 4 mg iv every 3 months for 12 months
Study: 2050831
Drug: Amiloride 10
Normalized name: amiloride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10 mg daily
Study: 12949315
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension and cromolyn sodium
Study: 6365017
Drug: Methadyl acetate
Normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadyl acetate six days a week with diminishing doses on three days
Study: 30497530
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy without bevacizumab
Study: 21052775
Drug: Radiotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy followed by adjuvant temozolomide (150‐200 mg/m(2) for 5 days every 28 days)
Study: 21962214
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (500 mg/kg)
Study: 27860389
Drug: Canrenone 100
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 100 mg
Study: 17505429
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (ET) using Hemobahn/Viabahn endograft
Study: 7378115
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (hydrous solution, 1 mg F−/100 ml)
Study: 10908898
Drug: Levetiracetam 3000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 3000 mg/day
Study: 15093870
Drug: Ranolazine 1000
Normalized name: ranolazine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 1000 mg twice daily
Study: 25757171
Drug: Clopidogrel (Listab)
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel (Listab) 75 mg/day
Study: 19691426
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once daily
Study: 97033
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg DSCG inhaled four times daily for 3 days
Study: 4758424
Drug: Recently produced
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recently produced Lanoxin tablets (1.5 mg dose)
Study: 2318517
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hydrochlorothiazide (50-100 mg)
Study: 29122360
Drug: More rigorous
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More rigorous dose calculation algorithm
Study: 17235610
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg/day
Study: 15842136
Drug: Mosapride Citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride Citrate tablet
Study: 8351043
Drug: Chewable antiplaque
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable antiplaque preparation containing chlorhexidine, fluoride, and xylitol
Study: 3528964
Drug: Etoposide therapy
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide therapy
Study: 3528964
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy (VBAMDex)
Study: 19935070
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg
Study: 2610509
Drug: Cefixime 2
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 2 h before antacid
Study: 2610509
Drug: Cefixime 2
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 2 h after antacid